Using Nanoparticles to Reduce Drug Toxicity in Pancreatic Cancer Patients

Sometimes the treatment for a disease can be almost as dangerous as the ailment it seeks to cure. In the case of pancreatic cancer, one of the most effective drug regimens, FOLFIRINOX, contains a highly toxic drug called irinotecan. Huan Meng and Xiangsheng Liu are authors on a recent paper in ACS Nano on a way to use nanoparticles to help reduce the toxicity of the regimen. Their research describes the custom-designing of a mesoporous silica nanoparticle platform to deliver irinotecan directly to cancerous cells, instead of releasing it into the rest of the body.

Watch them describe their research:

Want to learn more? Read their research in ACS Nano.

Get stories like this one in your inbox every month. Sign up for a custom newsletter from ACS Axial.

If you have comments or questions for the author of this post, please e-mail: